|Bid||153.50 x 100|
|Ask||165.96 x 100|
|Day's Range||155.68 - 158.08|
|52 Week Range||74.24 - 168.07|
|PE Ratio (TTM)||33.84|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
CNBC's Meg Tirrell reports on the results of Roche's cancer and hemophilia treatment trials and how those results are affecting other pharmaceutical companies.
Roche CEO Severin Schwan told CNBC that the company's strategy "has always been and remains to move the standard of care, to bring better medicines."
CNBC’s Carolin Roth talks about the performance of Roche in light of its recent earnings release, with comment from the company’s CEO Severin Schwan.
Zacks.com highlights: Jones Lang LaSalle, Rogers, PBF Energy, Westlake Chemical and DXC Technology
The search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Rogers Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Rogers Corp. Here are 5 ETFs with the largest exposure to ROG-US. Comparing the performance and risk of Rogers Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Rogers Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Rogers Corp. – Park Electrochemical Corp., Benchmark Electronics, Inc. and 3M Company (PKE-US, BHE-US and MMM-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)
The Rogers, Connecticut-based company said it had net income of $1.13 per share. Earnings, adjusted for costs related to mergers and acquisitions and restructuring costs, were $1.33 per share. The specialty ...
A Supreme Court ruling is likely to stir interest in more than a dozen biosimilars either approved for the market or in later stages of the R&D pipeline.